Samuel Wagner, PhD
Articles
January 17th 2017
An Expanded Portfolio of Survival Metrics for Assessing Anticancer Agents
Jennifer Karweit, MS Srividya Kotapati, PharmD Samuel Wagner, PhD James W. Shaw, PhD, PharmD, MPH Steffan W. Wolfe, BA Amy P. Abernethy, MD, PhD
A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
